Guideline-Directed Cardiovascular Medicines

Uses

How it works

Benefits

Evidence quality

Highlighted claims

• Overall uptake of guideline-directed cardiovascular medicines was high but varied by condition, medicine class, and frailty status. — Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study
• Multimorbidity was associated with greater use of several cardiovascular medicines while frailty was associated with lower use across all studied conditions. — Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study
• Further outcomes research is needed to quantify the risks and benefits of cardiovascular medicines in patients with multimorbidity and frailty because these groups are under-represented in clinical trials. — Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study
• The findings support shared decision making with patients and carers when considering cardiovascular medicines in adults with frailty. — Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study
• Discharge medication orders may underestimate guideline-directed therapy because temporarily held medicines may not have been restarted before discharge. — Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study